Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years

NCT01504347 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01504347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01504347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Blind, Phase 1/2 Clinical Study to Investigate the Safety and Immunogenicity of a Multivalent Recombinant OspA Lyme Borreliosis Vaccine (mv rOspA LB Vaccine) in Healthy Subjects Aged 18 to 70 Years
Lead sponsor
Baxalta now part of Shire
Phase
Phase 1/2
Overall status
Completed
Start date
March 1, 2011
Completion date
February 28, 2014
Enrollment
1,630 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

prophylaxis of lyme borreliosis